biote Corp.
BTMD Nasdaq· Medicinal Chemicals & Botanical Products
Last close · Oct 26, 2026
$1.15
KIRA · Stoqly’s AI analyst, in plain words
- biote Corp. had $192M of revenue in fiscal 2025, down 2.5% on the year before.
- Its operating margin was 18.5%, up 2.5 pts: of every 100 in sales, about 18 is left after running the business.
- biote Corp. made $27.0M of net profit in fiscal 2025.
- Free cash flow was $30.2M in fiscal 2025, 15.7% of revenue.
- biote Corp. returned $5.1M to shareholders in fiscal 2025, 17% of free cash flow. The diluted share count rose 7.0%.
- biote Corp. owes $79.0M more than it holds in cash, about 2.0 years of operating profit.
Market cap
$32.9M
P/E
11.5x
Revenue
$192M
Net income
$27.0M
Free cash flow
$30.2M
Operating margin
18.5%
biote Corp. in 30 seconds · fiscal 2025
Are sales growing?
−2.5%
No. Sales fell 2.5% last year.
Does it make a profit?
14.1%
Yes. It keeps 14.1% of every sale as profit.
Does profit turn into cash?
15.7%
Yes. 15.7% of sales ends up as free cash.
Is debt under control?
2.0x
Keep an eye on it. Repaying its debt would take 2.0 years of operating profit.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
11.5x
One share costs 11.5 times its yearly profit per share.
What biote Corp. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- biote Corp.
- CIK
- 0001819253
biote Corp. · BTMD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $139M | $165M | $185M | $197M | $192M |
| Revenue growth | — | 18.3% | 12.4% | 6.4% | −2.5% |
| Operating margin | 24.8% | −36.8% | 15.5% | 16.0% | 18.5% |
| Net income | $11.1M | −$1.0M | $3.3M | $3.2M | $27.0M |
| Net margin | 8.0% | −0.6% | 1.8% | 1.6% | 14.1% |
| Diluted EPS | — | −$0.12 | $0.13 | $0.09 | $0.74 |
| Cash | |||||
| Cash from operations | $33.7M | −$9.2M | $26.9M | $45.2M | $35.2M |
| Capital expenditure | $1.4M | $0.3M | $0.4M | $6.4M | $5.0M |
| Free cash flow | $32.3M | −$9.5M | $26.5M | $38.8M | $30.2M |
| FCF margin | 23.2% | −5.8% | 14.3% | 19.7% | 15.7% |
| Dividends paid | $11.4M | $12.9M | $8.7M | $4.7M | $1.7M |
| Share buybacks | — | — | — | $5.6M | $3.4M |
| Share count change | — | — | 219.0% | 33.3% | 7.0% |
| Debt and strength | |||||
| Cash and short-term investments | $0.1M | $79.2M | $89.0M | $39.3M | $24.1M |
| Debt incl. finance leases | $37.0M | $122M | $116M | $109M | $103M |
| Shareholders' equity | $4.1M | −$44.5M | −$29.4M | −$106M | −$58.5M |
| Net debt / EBITDA | 1.0x | — | 0.8x | 2.0x | 2.0x |
| Current ratio | 2.7x | 5.4x | 5.5x | 1.3x | 1.2x |
| Returns and quality | |||||
| Return on capital | 83.6% | — | — | — | 146.1% |
| Return on equity | 269.4% | — | — | — | — |
| Return on tangible equity | 269.4% | — | — | — | — |
| Piotroski F-score | — | 1 | 6 | 5 | 5 |
| Altman Z'' | 8.2 | −0.4 | 4.7 | −0.5 | 0.9 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
biote Corp. · BTMD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.15 a share, the company is worth $32.9M: 11.5 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001819253). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.